#5

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet | | of | |

Complete if Known	
Application Number	
Filing Date	
First Named Inventor	SHAHZI Iqbal
Group Art Unit	
Examiner Name	
Attorney Docket Number	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AS	1.	US 6060245		Sorge et al	05/09/2000	435/6
	2.	US 6017701		Sorge et al	01/25/2000	435/6
	3.	US 5958738		Linemann, et al	09/28/1999	435/91.2
	4.	US 5804382		Sytkowski, et al.	09/08/1998	435/6
	5.	US 5759780		Parker et al.	06/02/1998	435/6
	6.	US 5712127		Malek, et al.	01/27/1998	435/91.21
AS	7.	US 5525471		Zeng J.	06/11/1996	435/6

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

Examiner Signature	Alexander H. Spyrou	Date Considered	11/4/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	
Filing Date	
First Named Inventor	SHAHZI LOBOI
Group Art Unit	
Examiner Name	
Attorney Docket Number	

09/961089 09/24/01

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
AS	1.	Lennon, G.G. (2000) High-throughput gene expression analysis for drug discovery. DDT, 5(2), 59-66	
	2.	Artinger, M. et al. (1998) High throughput Analysis of Differential Gene Expression. J. Cell. Biochem. Suppl. 30/31, 286-296	
	3.	Berk, A.J. & Sharp, P.A. (1977) Sizing and mapping of early adenovirus mRNAs by gel electrophoresis of S1 endonuclease-digested hybrids. Cell 12, 721–732	
	4.	Lee, J.J. and Costlow, N.A. (1987) A molecular titration assay to measure transcript prevalence levels. Methods Enzymol. 152, 633–648	
	5.	Hedrick, S.M. et al. (1984) Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. Nature 308, 149–153	
	6.	Swaroop, A. et al. (1991) A simple and efficient cDNA library subtraction procedure: Isolation of human retina-specific cDNA clones. Nucleic Acids Res. 25, 1954	
	7.	Lisitsyn, N. et al. (1993) Cloning the differences between two complex genomes. Science 259, 946–951	
	8.	Greenberg, M.E. and Ziff, E.B. (1984) Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene. Nature 311, 433–438	
	9.	Marzluff, W.F. (1978) Transcription of RNA in isolated nuclei. Methods Cell Biol. 19, 317–331	
	10.	Manley, J.L. and Gefter, M.L. (1981) Transcription of mammalian genes in vitro. Gene Amplif. Anal. 2, 369–382	
AS	11.	Liang, P. and Pardee, A.B. (1992) Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257, 967–997	

Examiner Signature	Alexander H. Spiegel	Date Considered	11/4/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	
Filing Date	
First Named Inventor	SHAHZI IQBal
Group Art Unit	
Examiner Name	
Attorney Docket Number	

JC879 U.S. PTO 09/961089 09/24/01

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
AD	12.	Zhang, L. et al. (1997) Gene expression profiles in normal and cancer cells. Science 276, 1268–1272	
	13.	Polyak, K. et al. (1997) A model for p53-induced apoptosis. Nature 389, 300–305	
	14.	Schena, M. et al. (1995) Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270, 467–470	
	15.	Lennon, G.G. et al. (1996) The I.M.A.G.E. consortium: An integrated molecular analysis of genomes and their expression. Genomics 33, 151–152	
	16.	Heller, R.A. et al. (1997) Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc. Natl. Acad. Sci. U. S. A. 94, 2150–2155	
	17.	Schena, M. et al. (1996) Parallel human genome analysis:Microarray-based expression monitoring of 1000 genes. Proc.Natl.Acad.Sci. U.S.A. 93, 10614–10619	
	18.	Gress, T. et.al. (1992) Genome 3:609-619.	
	19.	Southern, E.M. (1975) J. Mol. Biol. 98:503-517.	
	20.	Gray, N.S. et al. (1998) Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281, 533–538	
	21.	Marton, M.J. et al. (1998) Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat. Med. 4, 1293–1301	
AD	22.	Braxton, S. and Bedilion, T. (1998) The integration of microarray information in the drug development process. Curr. Opin. Biotechnol. 9, 643–649	

Examiner Signature	Alexander H. Spiegel	Date Considered	11/4/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.